Top

News & Events

Client News

Client News

Health for Life Capital™ Further Expands Israeli Portfolio with Investment in Microbiome App Developer

Paris, France - Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces that it has invested in Israel-based personalized nutrition microbiome app company DayTwo through its Health for Life Capital™ investment vehicle, as part of a $12m series A fundraising.

Read more »

Mission Therapeutics Appoints Scientific Advisory Board

Cambridge, UK – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat serious diseases including mitochondrial diseases, neurodegeneration, inflammation and cancer, today announced the formation of its inaugural Scientific Advisory Board (SAB).
 

Read more »

BioGeneration Ventures Fund III Secures EUR 66m, exceeding EUR 50m target

Naarden, The Netherlands – BioGeneration Ventures (BGV), the early stage life sciences venture capital firm with funds focussed on European biotechnology companies, announces today an investment by the European Investment Fund (EIF) and other new investors in BGV III, taking the total capital commitments to EUR 66m, out of a maximum EUR 75m. The Fund is supported by the “InnovFin – EU Finance for Innovators” initiative under Horizon 2020 and the European Fund for Strategic Investments.

Read more »

Microbiotica Shortlisted for Biotech and Money’s ‘Life Science Spin-out of the Year’

Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics, is delighted to announce that it has been shortlisted for the ‘Life Science Spin-out of the Year’ category of the Biotech and Money 2017 Awards.

Read more »

Abcam announces first international Epigenetics conference in South Korea

Cambridge, UK – Abcam plc, a global leader in the supply of innovative life science reagents and tools, today announced its upcoming international conference “Epigenetic Regulatory Pathways”, to be held in Seoul, South Korea, from 26-28 June 2017. Korean and international experts will present their latest research on epigenetic disease pathways, as well as insights on related drug discovery and development.

Read more »

Clinigen signs exclusive supply agreements in Global Access

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, announces that its Idis Global Access (‘Idis GA’) division, has signed three further exclusive agreements to manage the supply and distribution of critical medicines on demand.

Read more »

Recce Constructs Automated Manufacturing Facility to Support Clinical Trials

Syndey, Australia - Recce Limited (ASX: RCE), a pre-clinical stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics, today announced it has completed construction of a wholly owned production facility in Macquarie Park Sydney with expected outputs capable of supporting RECCE® 327 through both Phase 1 and Phase 2 human trials.

Read more »

Beijing 4P Health Research Institute initiates China’s “100K Wellness Pioneer Project” using UniteGen and Sapientia™ integrated platform

Cambridge, UK - Congenica’s Sapientia™ clinical genome analysis software platform will be used by China-based UniteGen to carry out whole genome sequencing (WGS) processing and analysis as part of China’s “100K Wellness Pioneer Project”, hosted by Beijing 4P Health Research Institute.

Read more »

Microbiotica to Present at Microbiome Drug Development Summit

Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics, announces that its Chief Scientific Officer Dr Trevor Lawley will present at this year’s Microbiome Drug Development Summit, 27-29 June in Boston.

Read more »

Cell Medica acquires WT1 cancer immunotherapy from Cell and Gene Therapy Catapult

London – Cell Medica today announced the acquisition of Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult’s GMP manufacturing facility in Stevenage, UK. Financial terms were not disclosed.

Read more »

Recce Secures up to A$6.05 Million Investment Agreement with US Institutional Investor

SYDNEY, Australia -  Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics, today announced it had entered an agreement for a flexible funding commitment of up to A$6.05 million with The Australian Special Opportunity Fund LP (ASOF), providing capital to support Recce’s synthetic antibiotic through its Investigative New Drug (IND) Application to the Food and Drug Administration in the USA and Phase I clinical trials.

Read more »

LifeArc set to transform medical research landscape

London - LifeArc, the UK medical research charity previously known as MRC Technology1, today announced ambitious plans to improve the lives of patients suffering from diseases that present the greatest challenges to medical research. By investing up to £500 million2 over the next five years, LifeArc will seek to generate, fund and champion innovations in antimicrobials, neuroscience, personalised oncology and respiratory medicine.

Read more »

Medicxi launches first $300m late-stage life sciences fund Medicxi Growth 1 (MG1), backed by Novartis and Verily

London & Geneva & Jersey – Medicxi today announces the close of Medicxi Growth 1 (MG1), a new $300 million fund that will focus on growth stage companies in European life sciences.
With this new late stage fund, Medicxi will help fill a clear gap in Europe, where talented life sciences entrepreneurs do not have access to as much local financial support as their US-based counterparts to expand exciting opportunities into more mature companies.

Read more »

Crescendo Biologics Appoints Edward J. Stewart as Chief Business Officer

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), a company developing highly potent and differentiated Humabody® therapeutics, today announced that Edward J. “Tad” Stewart has joined the company as Chief Business Officer.

Read more »

Three New Studies Presented at ASCO Annual Meeting Demonstrate Benefits of MammaPrint® in Aiding Individualized Treatment Management for Early-Stage Breast Cancer Patients

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announced further details on three studies presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago earlier this week. These studies further demonstrate the clinical utility of Agendia’s MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test.

Read more »

Full year results: integration and growth seen across the Group, with 41% underlying increase in revenues

Cambridge, UK, 13 June 2017 - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has published its full year results for the year to 31 March 2017.

Read more »

‘Microbes and Me’ - how our understanding of the microbiome is pushing new horizons in research and spawning a US$0.5bn+ industry

Paris, France – 13 June 2017 – Rapidly advancing understanding of the relationship between humans and their symbiotic microbes, and how their imbalance (dysbiosis) triggers or contributes to diseases will transform opportunities for novel nutritional, diagnostic and therapeutic products, says a new report by Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector.

Read more »

Research published in Scientific Reports uses state-of-the-art CRISPR technology to validate relevance of the Dimerix Receptor-HIT technology in real time

MELBOURNE, Australia, 13 June 2017: Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company discovering and developing new therapeutic treatments identified using its proprietary assay technology today announced the publication of important research by Chief Scientific Advisor, Associate Professor Kevin Pfleger and colleagues in the leading peer reviewed journal Scientific Reports (1).

Read more »

Adherium Appoints New CEO to Drive Global Growth

Melbourne, Australia - Adherium Limited (ASX : ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced the appointment of Arik Anderson as Group Chief Executive Officer (CEO). Founder and past Group CEO, Garth Sutherland, welcomed the appointment of Arik as a key step in the next and important phase of Adherium’s global business growth, allowing him to focus on new areas of development while Mr Anderson focusses on the global business opportunities in front of the Company today.

Read more »

Dimerix hosts US key opinion leader meeting with NephCure Kidney International focused on development path of DMX-200 in kidney disease

MELBOURNE, Australia, 6th June 2017: Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company discovering and developing new therapeutic treatments identified using its proprietary assay technology said it has hosted a half-day meeting on Saturday 3 June 2017 in Baltimore, Maryland United States, with representatives from the patient advocacy group NephCure Kidney International and leading nephrologists from the US and Canada with representation from NephCure’s scientific advisory board and the NephCure Accelerating Cures Institute (NACI).

Read more »

F-star Expands its Relationship with Merck through a new Strategic Collaboration to Develop Bispecific Antibodies in Immuno-Oncology

Cambridge, UK – F-star, a biopharmaceutical company developing novel bispecific antibodies, announces today a new partnership with Merck, a leading science and technology company, for the development and commercialisation of five bispecific immuno-oncology antibodies.

Read more »

The PD-1 / PD-L1 Combination Therapies Revolution: New EP Vantage Report Sees Immuno-oncology Trials Triple and Keytruda Steal the Crown from Opdivo

LONDON, UK,  BOSTON, TOKYO – The battle to find a cure for cancer has led to an explosion in the number of clinical trials using anti-PD-1 and anti-PD-L1 antibodies combined with other therapeutic approaches, says a new report by EP Vantage, the wholly independent editorial arm of Evaluate, the trusted provider of life science commercial intelligence.

Read more »

Atomo Diagnostics’ HIV Self Test receives approval from Kenya Ministry of Health

Sydney, Australia - Multi-award winning medical device innovator Atomo Diagnostics today announced its pioneering HIV self test product has been approved for sale in Kenya.

Read more »

Hookipa Biotech Announces Nature Communications Publication Showing TheraT® Turns Cold Tumors Hot

Vienna, Austria - Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces publication in leading peer-reviewed publication Nature Communications of research data in a transgenic mouse model showing how its replicating viral vector platform TheraT® delivers potent innate immune activation including key alarmin signals.

Read more »

Bioverativ to acquire True North Therapeutics and the Abzena Inside portfolio product, TNT009

Cambridge, UK, 24 May 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, notes the announcement from Bioverativ Inc. (NASDAQ: BIVV), that it has entered into a definitive agreement to acquire True North Therapeutics for an upfront payment of $400 million plus assumed cash. True North investors are also eligible to receive additional payments of up to $425 million contingent on the achievement of future development, regulatory and sales milestones.

Read more »